<DOC>
	<DOCNO>NCT02003313</DOCNO>
	<brief_summary>The purpose double-blind study evaluate safety , reactogenicity immunogenicity Group A , C , Y W135 Meningococcal Polysaccharide Vaccine 2 30 years-old Children Adults . All subject receive 1 dose Group A , C , Y W135 Meningococcal Polysaccharide Vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Group A , C , Y W135 Meningococcal Polysaccharide Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Healthy permanent residence 230 year old . Subjects parent/guardian able attend schedule visit comply study procedure . Axillary temperature ≤37.0 ℃ . History meningitis infection vaccination meningococcal vaccine within past 6 month . Allergic history SAE vaccination , allergy , urticaria , dyspnea , angioedema , celialgia . Patients administer immunosuppressive agent , cytotoxicity factor corticosteroid 6 month precede vaccine trial . Receipt blood bloodderived product 3 month precede vaccination . Participation another clinical study investigate vaccine , drug 30 day precede vaccination . Receipt live virus vaccine 15 day precede vaccination . Receipt subunit vaccine inactivate vaccine 7 day vaccination . Febrile illness ( temperature ≥ 38°C ) 3 day acute illness/infection 7 day precede vaccination . Thrombocytopenia . History thyroid gland excision treatment thyroid gland disease last 12 month . Functional anatomic asplenia . History eclampsia , epilepsy , encephalopathy mental disease family disease . Chronic disease ( Down syndrome , diabetes , sickle cell anemia neurologic disease , GuillainBarre Syndrome ) . Known suspected disease , include : respiratory system disease , acute infection active stage chronic disease , HIV infection child mother , cardiovascular disease , acute hypertension , cancer treatment , skin disease , etc . In pregnancy lactation pregnant woman test plan Any condition , judgment investigator , may affect trial assessment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>safety , immunogenicity , Meningococcal Polysaccharide Vaccine</keyword>
</DOC>